Swedish Orphan Biovitrum AB (publ) (SWOBY)

Market Cap	9.90B
Revenue (ttm)	2.35B
Net Income (ttm)	351.03M
Shares Out	n/a
EPS (ttm)	1.02
PE Ratio	28.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	274
Average Volume	1,876
Open	14.00
Previous Close	n/a
Day's Range	14.00 - 14.00
52-Week Range	10.00 - 16.50
Beta	0.30
RSI	48.83
Earnings Date	Mar 31, 2025

About SWOBY

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology and Specialty Care. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for hae...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1939
• Employees: 1,806
• Stock Exchange: OTCMKTS
• Ticker Symbol: SWOBY

Financial Performance

In 2024, SWOBY's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK